Iovance's Update Provides Reassurance With Upcoming Lifileucel's FDA Action Date, Analyst Says
Portfolio Pulse from Vandana Singh
Iovance Biotherapeutics Inc announced regulatory and clinical updates related to its Phase 2 IOV-LUN-202 trial in post-anti-PD-1 non-small cell lung cancer (NSCLC). The FDA said that the design of the trial might be acceptable for accelerated approval of LN-145 TIL therapy for lung cancer patients. Iovance plans to enroll approximately 120 patients into the trial, with enrollment expected to be complete during 2H 2024. The FDA's Priority Review of the marketing application for lifileucel in advanced melanoma remains on track. HC Wainwright reiterates its Buy rating and $38 price target for Iovance.
July 10, 2023 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance's Phase 2 IOV-LUN-202 trial might be acceptable for accelerated approval of LN-145 TIL therapy for lung cancer patients. This positive news, along with HC Wainwright's reiterated Buy rating and $38 price target, could have a positive impact on Iovance's stock price.
The FDA's positive feedback on Iovance's Phase 2 IOV-LUN-202 trial and HC Wainwright's reiterated Buy rating and $38 price target are likely to boost investor confidence in the company, potentially leading to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100